IL155066A - תולדות 2 - אמינו - 2 - (2 - אתיל(מותמר)) פרופן - 1, 3 - דיאול היעילות בהכנת 2 - אמינופרופן - 1, 3 - דיאול - Google Patents

תולדות 2 - אמינו - 2 - (2 - אתיל(מותמר)) פרופן - 1, 3 - דיאול היעילות בהכנת 2 - אמינופרופן - 1, 3 - דיאול

Info

Publication number
IL155066A
IL155066A IL15506698A IL15506698A IL155066A IL 155066 A IL155066 A IL 155066A IL 15506698 A IL15506698 A IL 15506698A IL 15506698 A IL15506698 A IL 15506698A IL 155066 A IL155066 A IL 155066A
Authority
IL
Israel
Prior art keywords
compound
acid
reaction
present
ethyl
Prior art date
Application number
IL15506698A
Other languages
English (en)
Other versions
IL155066A0 (en
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of IL155066A0 publication Critical patent/IL155066A0/xx
Publication of IL155066A publication Critical patent/IL155066A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/16—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15506698A 1997-04-04 1998-04-03 תולדות 2 - אמינו - 2 - (2 - אתיל(מותמר)) פרופן - 1, 3 - דיאול היעילות בהכנת 2 - אמינופרופן - 1, 3 - דיאול IL155066A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8625597 1997-04-04
PCT/JP1998/001571 WO1998045249A1 (fr) 1997-04-04 1998-04-03 Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
IL155066A0 IL155066A0 (en) 2003-10-31
IL155066A true IL155066A (he) 2004-06-20

Family

ID=13881722

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
IL15506598A IL155065A (he) 1997-04-04 1998-04-03 תולדות -2אמינופרופן - 1, 3 - דיאול ותכשירי רוקחות המכילים אותן
IL15506698A IL155066A (he) 1997-04-04 1998-04-03 תולדות 2 - אמינו - 2 - (2 - אתיל(מותמר)) פרופן - 1, 3 - דיאול היעילות בהכנת 2 - אמינופרופן - 1, 3 - דיאול

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
IL15506598A IL155065A (he) 1997-04-04 1998-04-03 תולדות -2אמינופרופן - 1, 3 - דיאול ותכשירי רוקחות המכילים אותן

Country Status (18)

Country Link
US (2) US6214873B1 (he)
EP (2) EP1002792B1 (he)
JP (1) JP4045364B2 (he)
KR (1) KR100551931B1 (he)
CN (2) CN1137086C (he)
AT (2) ATE271028T1 (he)
AU (1) AU735853B2 (he)
BR (1) BR9808481A (he)
CA (1) CA2286315C (he)
DE (2) DE69830756T2 (he)
DK (2) DK1319651T3 (he)
ES (2) ES2226110T3 (he)
IL (3) IL132208A (he)
NZ (1) NZ500713A (he)
PT (2) PT1319651E (he)
RU (1) RU2198162C2 (he)
SI (2) SI1002792T1 (he)
WO (1) WO1998045249A1 (he)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
AU2001296536A1 (en) 2000-10-03 2002-04-15 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
WO2002064616A2 (en) 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
WO2002067915A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
ES2254675T3 (es) 2001-03-26 2006-06-16 Novartis Ag Derivados del 2-amino-propanol.
CN1236831C (zh) * 2001-05-21 2006-01-18 茵捷特数码浮质有限公司 用于经肺部途径递送蛋白质的组合物
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
BRPI0212894B8 (pt) 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
PL211954B1 (pl) * 2002-01-11 2012-07-31 Sankyo Co Związek, kompozycja farmaceutyczna oraz zastosowanie kompozycji farmaceutycznej
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CN100516024C (zh) * 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
RU2478378C2 (ru) * 2002-09-24 2013-04-10 Новартис Аг Органические соединения
NZ542622A (en) 2003-04-08 2009-01-31 Novartis Ag Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2008200368B2 (en) * 2003-04-08 2011-04-28 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2011205050B2 (en) * 2003-04-08 2014-01-30 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
WO2004096752A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1733724A4 (en) 2004-02-24 2010-07-07 Sankyo Co Aminoalcohol compound
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US7820703B2 (en) 2004-05-06 2010-10-26 University Of Virginia Patent Foundation Lysophosphatidic acid receptor selective antagonists
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
PT1772145E (pt) * 2004-07-16 2011-05-27 Kyorin Seiyaku Kk Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
JP4919374B2 (ja) * 2004-07-29 2012-04-18 第一三共株式会社 免疫抑制剤としての医薬組成物
WO2006010630A1 (en) 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds
MX2007001661A (es) * 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
JP4792400B2 (ja) * 2004-10-12 2011-10-12 杏林製薬株式会社 ２−アミノ−２−［２−［４−（３−ベンジルオキシフェニルチオ）−２−クロロフェニル］エチル］−１，３−プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体
RU2478384C2 (ru) 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
CA2595960A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
TW200702326A (en) * 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
WO2008018427A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
CN102579387A (zh) 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
TWI439263B (zh) 2007-06-14 2014-06-01 Mitsubishi Tanabe Pharma Corp 胺化合物及其醫藥用途
DE102007039954A1 (de) * 2007-08-23 2009-02-26 Henkel Ag & Co. Kgaa Reduktive Entfärbung keratinhaltiger Fasern
EP3733161A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
ES2665336T3 (es) 2012-04-23 2018-04-25 Mitsubishi Tanabe Pharma Corporation Compuesto amina y su uso para propósitos médicos
CN110862409B (zh) * 2019-12-04 2021-08-20 江南大学 一种制备含二元醇结构的硅烷类化合物及其改性水性聚氨酯的方法
US20220153684A1 (en) * 2020-11-13 2022-05-19 Shivalik Rasayan Limited Process for preparation of fingolimod hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660488A (en) * 1965-07-16 1972-05-02 Phillips Petroleum Co 2-halo-alkylene- and -cyclopentylene-2-amino-propane 1 3-diols
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DK0778263T3 (da) * 1994-08-22 2002-04-22 Mitsubishi Pharma Corp Benzenforbindelser og farmaceutisk anvendelse af disse

Also Published As

Publication number Publication date
CN1290819C (zh) 2006-12-20
USRE39072E1 (en) 2006-04-18
IL155065A0 (en) 2003-10-31
DE69825056T2 (de) 2005-08-25
JP4045364B2 (ja) 2008-02-13
IL155065A (he) 2004-01-04
EP1319651B1 (en) 2005-06-29
ATE298740T1 (de) 2005-07-15
ATE271028T1 (de) 2004-07-15
US6214873B1 (en) 2001-04-10
SI1319651T1 (en) 2005-10-31
CN1480450A (zh) 2004-03-10
SI1002792T1 (en) 2004-12-31
KR20010006004A (ko) 2001-01-15
ES2226110T3 (es) 2005-03-16
BR9808481A (pt) 2000-05-23
RU2198162C2 (ru) 2003-02-10
WO1998045249A1 (fr) 1998-10-15
CA2286315C (en) 2007-03-06
EP1002792A4 (en) 2002-03-20
CN1137086C (zh) 2004-02-04
AU6523098A (en) 1998-10-30
EP1002792B1 (en) 2004-07-14
NZ500713A (en) 2000-07-28
ES2240868T3 (es) 2005-10-16
PT1002792E (pt) 2004-12-31
CA2286315A1 (en) 1998-10-15
DK1319651T3 (da) 2005-08-01
KR100551931B1 (ko) 2006-02-16
DE69825056D1 (de) 2004-08-19
IL132208A (en) 2003-07-31
EP1319651A2 (en) 2003-06-18
PT1319651E (pt) 2005-09-30
CN1259117A (zh) 2000-07-05
IL132208A0 (en) 2001-03-19
DE69830756T2 (de) 2006-05-04
DE69830756D1 (de) 2005-08-04
EP1319651A3 (en) 2004-01-02
IL155066A0 (en) 2003-10-31
AU735853B2 (en) 2001-07-19
EP1002792A1 (en) 2000-05-24
DK1002792T3 (da) 2004-11-22

Similar Documents

Publication Publication Date Title
EP1319651B1 (en) 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
US6197829B1 (en) External preparation of 2-amino-2-(2-(4-octylphenyl)ethyl) propane-1,3-diol or pharmaceutically acceptable salts thereof for topical administration
WO2005014525A2 (en) Bi-aryl compound having immunosuppressive activity
US20090176744A1 (en) Deuterated fingolimod
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
AU2002339071B2 (en) Silicon compounds
US20100184862A1 (en) Prostacyclin derivatives
AU2002339071A1 (en) Silicon compounds
WO2005014603A1 (en) Phosphinane compounds with immunomodulating activity
FR2656221A1 (fr) Compositions therapeutiques a base de derives du glycerol.
EP1562611B1 (en) Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
MXPA99009124A (en) 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH0322394B2 (he)
JPH05117236A (ja) ジクロロアニリン化合物
TW202339766A (zh) 非環狀硫醇前藥
JP2009522380A (ja) 抗腫瘍活性を有するタキソール誘導体
JPH0322395B2 (he)
WO2004094436A1 (en) 1-(2-amino-1-phenyl-ethyl) 1- silacyclohexan-1- ol derivatives and use thereof in the preparation of a medicament

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees